OBJECTIVE: To examine venous partial pressure of oxygen (PvO(2)), transcutaneous oxygen tension (tcPO(2)), and VO(2)MAX in a normobaric environment after a single hyperbaric oxygen (HBO(2)) treatment. METHODS: This was a prospective study of conditions after the intervention compared with baseline. The participants were 10 moderately trained (VO(2)MAX = 57.6 ml/kg/min) men. Two HBO(2) treatments consisting of breathing 95% oxygen at 2.5 atmospheres absolute (ATA) for 90 minutes were administered on non-consecutive days. Baseline testing included measures of VO(2)MAX, tcPO(2), and anthropometry. At 6.0 (1.0) minutes after the first HBO(2) treatment, a VO(2)MAX test was performed. After the second HBO(2) treatment, leg and chest tcPO(2) and PvO(2) were monitored for 60 minutes. RESULTS: VO(2)MAX, running time, and peak blood lactate were not altered after the HBO(2) treatment. Leg tcPO(2) was lower (p = 0.003) and chest tcPO(2) was unchanged after the HBO(2) treatment compared with baseline values. PvO(2) was significantly (p<0.001) lower in the first three minutes after treatment than subsequent values, but no other differences were found. CONCLUSIONS: A single HBO(2) treatment at 2.5 ATA for 90 minutes does not raise PvO(2), tcPO(2), or VO(2)MAX in a normobaric, normoxic environment.
OBJECTIVE: To examine venous partial pressure of oxygen (PvO(2)), transcutaneous oxygen tension (tcPO(2)), and VO(2)MAX in a normobaric environment after a single hyperbaric oxygen (HBO(2)) treatment. METHODS: This was a prospective study of conditions after the intervention compared with baseline. The participants were 10 moderately trained (VO(2)MAX = 57.6 ml/kg/min) men. Two HBO(2) treatments consisting of breathing 95% oxygen at 2.5 atmospheres absolute (ATA) for 90 minutes were administered on non-consecutive days. Baseline testing included measures of VO(2)MAX, tcPO(2), and anthropometry. At 6.0 (1.0) minutes after the first HBO(2) treatment, a VO(2)MAX test was performed. After the second HBO(2) treatment, leg and chest tcPO(2) and PvO(2) were monitored for 60 minutes. RESULTS: VO(2)MAX, running time, and peak blood lactate were not altered after the HBO(2) treatment. Leg tcPO(2) was lower (p = 0.003) and chest tcPO(2) was unchanged after the HBO(2) treatment compared with baseline values. PvO(2) was significantly (p<0.001) lower in the first three minutes after treatment than subsequent values, but no other differences were found. CONCLUSIONS: A single HBO(2) treatment at 2.5 ATA for 90 minutes does not raise PvO(2), tcPO(2), or VO(2)MAX in a normobaric, normoxic environment.
Authors: James D Reynolds; Trevor Jenkins; Faisal Matto; Ryan Nazemian; Obada Farhan; Nathan Morris; John M Longphre; Douglas T Hess; Richard E Moon; Claude A Piantadosi; Jonathan S Stamler Journal: Clin Pharmacol Ther Date: 2018-01-17 Impact factor: 6.875
Authors: James D Reynolds; Kyla M Bennett; Anthony J Cina; Diana L Diesen; Matthew B Henderson; Faisal Matto; Andrew Plante; Rachel A Williamson; Keivan Zandinejad; Ivan T Demchenko; Douglas T Hess; Claude A Piantadosi; Jonathan S Stamler Journal: Proc Natl Acad Sci U S A Date: 2013-06-24 Impact factor: 11.205
Authors: James D Reynolds; Gregory S Ahearn; Michael Angelo; Jian Zhang; Fred Cobb; Jonathan S Stamler Journal: Proc Natl Acad Sci U S A Date: 2007-10-11 Impact factor: 11.205
Authors: Carlos Burgos; Carlos Henríquez-Olguín; David Cristóbal Andrade; Rodrigo Ramírez-Campillo; Oscar F Araneda; Allan White; Hugo Cerda-Kohler Journal: J Nutr Metab Date: 2016-12-19
Authors: Faisal Matto; Peter C Kouretas; Richard Smith; Jacob Ostrowsky; Anthony J Cina; Douglas T Hess; Jonathan S Stamler; James D Reynolds Journal: Clin Transl Sci Date: 2017-12-12 Impact factor: 4.689